CNTA
Centessa Pharmaceuticals plc
NASDAQ · Healthcare · Biotechnology · GB
$40.50
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 15.0M | — | 6.9M | — |
| Cost of Revenue | 238.6K | — | — | — | — |
| Gross Profit | (238.6K) | 15.0M | — | 6.9M | — |
| Operating Expenses | |||||
| R&D Expense | 198.7M | 172.2M | 150.2M | 124.4M | 155.1M |
| SG&A Expense | 58.0M | 50.5M | 50.8M | 53.7M | 55.2M |
| General & Admin Expense | 58.0M | 50.5M | 50.8M | 53.7M | 55.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | 2.0M |
| Total Operating Expenses | 256.7M | 222.7M | 201.1M | 178.1M | 212.3M |
| Cost and Expenses | 256.6M | 222.7M | 201.1M | 178.1M | 212.3M |
| Operating Income (EBIT) | (256.7M) | (207.7M) | (201.1M) | (171.3M) | (212.3M) |
| Non-Operating | |||||
| Interest Income | 17.8M | 20.5M | 14.0M | 10.5M | 244.0K |
| Interest Expense | 11.3M | 11.5M | 10.1M | 9.9M | 7.3M |
| Net Interest Income | 6.5M | 9.1M | 3.9M | 570.0K | (7.0M) |
| Other Non-Op Income/Expense | 7.3M | 12.0M | (31.9M) | (4.9M) | (4.7M) |
| Non-Operating Income (excl Interest) | 4.8M | (23.4M) | 21.8M | (5.0M) | (2.6M) |
| EBT (Pre-Tax Income) | (249.4M) | (195.7M) | (232.9M) | (176.1M) | (217.0M) |
| Income Tax Expense | 1.3M | 1.8M | 2.8M | (25.1M) | (747.0K) |
| Bottom Line | |||||
| Net Income | (250.6M) | (197.5M) | (235.8M) | (151.1M) | (216.2M) |
| Earnings from Cont. Ops | (250.6M) | (197.5M) | (235.8M) | (151.1M) | (216.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (250.6M) | (197.5M) | (235.8M) | (151.1M) | (216.2M) |
| Per Share | |||||
| Basic EPS | ($1.78) | ($1.46) | ($2.06) | ($1.57) | ($2.31) |
| Diluted EPS | ($1.78) | ($1.46) | ($2.06) | ($1.57) | ($2.31) |
| Revenue Per Share | $0.00 | $0.11 | $0.00 | $0.07 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 153.5M | 135.7M | 114.5M | 96.2M | 93.4M |
| Diluted Shares Outstanding | 153.5M | 135.7M | 114.5M | 96.2M | 93.4M |
| Profitability Metrics | |||||
| EBITDA | (260.6M) | (183.3M) | (221.9M) | (165.4M) | (209.5M) |
| D&A | 942.6K | 921.0K | 942.0K | 810.0K | 131.0K |
| EBIT | (261.5M) | (184.3M) | (222.8M) | (166.2M) | (209.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026